袁 权

袁权

教授

电子邮箱yuanquan@xmu.edu.cn


主要学习经历:

2001-2005, 厦门大学, 生物科学, 理学学士

2005-2012, 厦门大学, 生物化学与分子生物学, 理学博士


科研工作经历:

2009-至今, 厦门大学NIDVD, 病毒性肝炎研究组, 组长

2012-2015, 厦门大学公共卫生学院, 助理教授

2016-2019, 厦门大学公共卫生学院, 副教授

2019-至今, 厦门大学公共卫生学院, 教授


简介:

2003开始从事乙型病毒性肝炎创新诊疗技术和药物相关研究,共发表SCI论文80余篇,其中作为第一/共一/通讯作者在GutNature CommunicationsSmall MethodsScience Translational Medicine等杂志发表研究论文20余篇,已有4项发明专利获得国内外11件授权,研究成果转化的诊断产品累计10项获得中国NMPA注册证、6项欧盟CE认证,多次获得福建省及厦门市科技进步奖等荣誉。


主要研究方向:

围绕乙型病毒性肝炎创新诊疗技术和药物这一目标开展分子病毒学、免疫学、临床检验诊断学、流行病学和转化医学研究,具体主要包括:

1)针对持续性病毒感染的治疗性抗体与治疗性疫苗研究;

2)慢性乙型肝炎治疗应答和转归指导预测诊断新靶标研究;

3)模拟人类HBV感染致病的细胞与动物模型研究;

4HBV感染及其相关疾病的血清与分子流行病学研究;

5)持续性病毒感染与肿瘤的免疫逃逸机制及治疗新技术。


5年代表论文:

  1. Zhang Y#, Wang S#, Wu Y#, Hou W#, Yuan L#, Shen C#, Wang J, Ye J, Zheng Q, Ma J, Xu J, Wei M, Li Z, Nian S, Xiong H, Zhang L, Shi Y, Fu B, Cao J, Yang C, Li Z, Yang T, Liu L, Yu H, Hu J, Ge S, Chen Y, Zhang T, Zhang J, Cheng T*, Yuan Q*, Xia N*. Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors. Small Methods. 2021 Feb 15;5(2):2001031. (IF:12.130)

  2. Wang SJ, Chen ZM, Wei M, Liu JQ, Li ZL, Shi TS, Nian S, Fu R, Wu YT, Zhang YL, Wang YB, Zhang TY, Zhang J, Xiong JH, Tong SP, Ge SX, Yuan Q, Xia NS. Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection. Emerg Microbes Infect. 2021 Dec;10(1):37-50. (IF: 5.776)

  3. Le Chang#, Wangheng Hou#, Lei Zhao#, Yali Zhang#, Yanbin Wang, Linfeng Wu, TingtingXu, Lilin Wang, Juan Wang, Jian Ma, Lan Wang, Junpeng Zhao, Jing Xu, Juan Dong, YingYan, Ru Yang, Yu Li, Fei Guo, Wenjuan Cheng, Yingying Su, Jinfeng Zeng, Wei Han, Tong Cheng, Jun Zhang, Quan Yuan*, Ningshao Xia, Lunan Wang*. Nature Communications, 2021, Accepted. (IF: 12.121)

  4. Zhao, J. #, Yuan, Q. #, Wang, H. #, Liu, W. #, Liao, X. #, Su, Y. #, Wang, X., Yuan, J., Li, T., Li, J., Qian, S., Hong, C., Wang, F., Liu, Y., Wang, Z., He, Q., Li, Z., He, B., Zhang, T., Fu, Y., … Zhang, Z. (2020). Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 71(16), 2027–2034. (IF:8.313)

  5. Lu J#, Lu G#, Tan S#, Xia J#, Xiong H#, Yu X, Qi Q, Yu X, Li L, Yu H, Xia N, Zhang T*, Xu Y*, Lin J*. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Research. 2020 Oct;30(10):936-939.(IF:20.507)

  6. Zhang TY#, Guo XR#, Wu YT#, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Chen PJ, Zhang J*, Yuan Q* and Xia NS*. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut. 2020 Feb;69(2):343-354. (IF:19.819)

  7. Zhang TY#, Chen HY#, Cao JL#, Xiong HL, Li TL, Kang XZ, Zhao JH, Yin B, Yuan Q*, Xue D*, Xia NS*, Yuan YA. Structural and functional analyses of the Hepatitis B virus X protein BH3-like domain and its interaction with Bcl-xL. Nature Communications. 2019, 10: 3192. (IF: 12.121)

  8. Zhang TY†, Guo XR†, Wu YT†, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Chen PJ, Zhang J*, Yuan Q* and Xia NS*. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut. 2019. (IF: 19.819)

  9. Yuan L†, Zhang Y†, Liu X†, Chen Y, Zhang L, Cao J, Li X, Wang M, Wu K, Zhang J, Liu G, Tang Q, Yuan Q*, Cheng T*, Xia N*. Agonist c-Met Monoclonal Antibody Augments the Proliferation of hiPSC-derived Hepatocyte-Like Cells and Improves Cell Transplantation Therapy for Liver Failure in Mice. Theranostics. 2019; 9(7):2115-2128. (IF: 8.579)

  10. Zhang YL†, Gao Y†, Cao JL, Zhao JH, Zhang TY, Yang CL, Xiong HL, Wang YB, Ou SH*, Cheng T, Chen CR*, Yuan Q*, Xia NS. Robust in vitro assay for analyzing the neutralization activity of serum specimens against hepatitis B virus. Emerg Microbes Infect. 2019;8(1):724-733. (IF: 5.776)

  11. Liu X†, Yuan L†, Zhang L, Mu Y, Li X, Liu C, Lv P, Zhang Y, Cheng T, Yuan Q*, Xia N, Chen X, Liu G*. Bioinspired Artificial Nanodecoys for Hepatitis B Virus. Angewandte chemie-international edition. 2018; 57(38):12499-12503. (IF: 12.959)

  12. Zhang JF†, Xiong HL†, Cao JL, Wang SJ, Guo XR, Lin BY, Zhang Y, Zhao JH, Wang YB, Zhang TY*, Yuan Q*, Zhang J, Xia NS. A cell-penetrating whole molecule antibody targeting intracellular HBx suppress hepatitis B virus via TRIM21-dependent pathway, Theranostics.2018, 8(2): 549-562. (IF: 8.579)

  13. Zhang TY†, Yuan Q†*, Zhao JH, Zhang YL, Yuan LZ, Lan Y, Lo YC, Sun CP, Wu CR, Zhang JF, Zhang Y, Cao JL, Guo XR, Liu X, Mo XB, Luo WX, Cheng T, Chen YX, Tao MH, Shih JW, Zhao QJ, Zhang J, Chen PJ, Yuan YA*, Xia NS*, Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut, 2016, 65(4): 658-71. (IF: 19.819)

  14. Fan F†, He Z†, Kong LL†, Chen Q†, Yuan Q†, Zhang S, Ye J, Liu H, Sun X, Geng J, Yuan L, Hong L, Xiao C, Zhang W, Sun X, Li Y, Wang P, Huang L, Wu X, Ji Z, Wu Q, Xia NS, Gray NS, Chen L, Yun CH*, Deng X*, Zhou D*. Pharmacological targeting of kinases mst1 and mst2 augments tissue repair and regeneration. Science Translational Medicine, 2016; 8(352), 352ra108. (IF: 16.304)

  15. Fan R†, Sun J†, Yuan Q†, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N*, Hou J*. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2016, 65(2):313-20. (IF: 19.819)


授权发明专利:

(1) 袁权,张天英,罗文新,陈毅歆,张军,夏宁邵,用于治疗HBV感染及相关疾病的多肽及抗体。美国(US9751914, 10246494B2) 、澳大利亚(AU2013276015B2)、加拿大(CA2876020);日本(JP6440259)、韩国(KR101944263)


主持或参加科研项目(课题)情况:

  1. 科技重大专项, 2020YFC0843400, 新型冠状病毒(2019-nCoV)抗体快速检测试剂盒的研制, 2020/2-2020/4, 6.00万元, 已结题, 参与

  2. 国家基金重大国际(地区)合作研究项目, U1905205, 乙肝病毒核心抗体水平作为疾病转归预测新靶标的病毒宿主互作机制与临床转化研究, 2020/1-2023/12, 227.00万元, 在研, 主持

  3. 厦门大学科技创新项目, 00000000, 高层次人才科研启动费(师资队伍)-袁权南墙B计划人才, 2019/7-2019/12, 70.00万元, 已结题, 主持

  4. 国家基金面上项目, 81871316, 表位嵌合型类病毒颗粒疫苗对慢性HBV感染的治疗作用与机制, 2019/1-2022/12, 57.00万元, 在研, 主持

  5. 厦门大学科技创新项目, 20720190124, 慢性HBV感染中核心抗体水平的调控机制, 2019/1-2019/12, 15.00万元, 已结题, 主持

  6. 科技重大专项, 2017ZX10202203-009-003, 靶向HBV cccDNA药物高通量筛选体系的构建, 2019/1-2020/12, 200.00万元, 已结题, 主持

  7. 厦门大学科技创新项目, 20720160063, 基于B细胞表位的乙肝治疗性疫苗研究, 2015/12-2017/12, 50.00万元, 已结题, 主持

  8. 福建省自然科学基金杰出青年基金, 2015J06018, 抗体对慢性病毒性感染的治疗作用及机制研究, 2015/4-2018/7, 30.00万元, 已结题, 主持

  9. 国家基金面上项目, 81371819, 隐匿性乙型肝炎病毒感染分子机制的细胞及动物模型验证研究, 2014/1-2017/12, 70.00万元, 已结题, 主持

 

 

上一条:张天英 下一条:吴 婷

国家传染病诊断试剂与疫苗工程技术研究中心(厦门大学)  地址:中国福建省厦门市翔安区翔安南路厦门大学翔安校区
电话:0592-2183111 传真:0592-2181258  邮编:361102
ICP备案号:D200327